Cas no 3796-63-2 ((5E,9E,13E)-Teprenone)
(5E,9E,13E)-Teprenone Chemical and Physical Properties
Names and Identifiers
-
- Teprenone
- E,E,E-geranylgeranylacetyl
- (E,E,E)-geranylgeranylacetone
- E-0671
- (5E,9E,13E)-6,10,14,18-tetramethyl-nonadeca-5,9,13,17-tetraen-2-one
- (5E,9E,13E)-6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetren-2-one
- 2-Oxo-6,10,14,18-tetramethyl-nonadecatetraen-(5.9.13.17)
- 6,10,14,18-tetramethyl-nonadeca-5t,9t,13t,17-tetraen-2-one
- 5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl-, (E,E,E)-
- 6,10,14,18-Tetramethyl-nonadeca-5t,9t,13t,17-tetraen-2-on
- (5E,9E,13E)-Teprenone
- 5,9,13,17-Nonadecatetraen-2-one,6,10,14,18-tetramethyl-,(E,E,E)
- (E,E,E)-GERANYLGERANYL ACETONE
- BCP11723
- SR-01000944917
- (5E,9E,13E)-6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraen-2-one
- Geranylgeranylacetone
- Teprenonum
- Teprenona
- SBI-0654108.0001
- 6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
- CS-3560
- (9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
- Selbex
- SCHEMBL157511
- UNII-S8S8451A4O
- SR-01000944917-1
- Ea-0671
- HY-B0779
- Q-201789
- Geranylgeranyl acetone
- Tetraprenylacetone
- (5E,9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
- Selbelle
- (5Z,9Z,13Z)-Geranylgeranylacetone
- CHEBI:31649
- 5,9,13,17-NONADECATETRAEN-2-ONE, 6,10,14,18-TETRAMETHYL-
- BRD-K11510141-001-02-6
- 6809-52-5
- s5006
- SCHEMBL157509
- DTXSID901166719
- CAS-6809-52-5
- Q7701388
- Teprenone [INN:JAN]
- (5Z,9Z,13E)-Geranylgeranylacetone
- 57B67OXM8F
- DTXCID9028546
- 3796-63-2
- S8S8451A4O
- DTXSID6048620
- E-671
- Tox21_112960
- NCGC00182034-01
- (E,E,E)-Geranylgeranyl Acetone; Tetraprenylacetone; (E,E,E)-6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraen-2-one
- 5,9,13,17-NONADECATETRAEN-2-ONE, 6,10,14,18-TETRAMETHYL-, (5E,9E,13E)-
- BRD-K11510141-001-01-8
- BRD-K11510141-001-03-4
- Teprenonum [INN-Latin]
- CCG-267813
- DA-48695
- Teprenona [INN-Spanish]
- AKOS015894922
- CHEMBL79686
- UNII-57B67OXM8F
- (5E,9E,13E)-Geranylgeranylacetone
- A12751
-
- MDL: MFCD00869547
- Inchi: 1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+
- InChI Key: HUCXKZBETONXFO-NJFMWZAGSA-N
- SMILES: O=C(C)CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C
Computed Properties
- Exact Mass: 660.58500
- Monoisotopic Mass: 330.292265831g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 1
- Heavy Atom Count: 24
- Rotatable Bond Count: 12
- Complexity: 482
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 3
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 3
- XLogP3: 7.4
- Topological Polar Surface Area: 17.1?2
Experimental Properties
- PSA: 34.14000
- LogP: 15.00260
(5E,9E,13E)-Teprenone Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-B0779A-10mM*1mLinDMSO |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.82% | 10mM*1mLinDMSO |
¥1650 | 2022-09-01 | |
| MedChemExpress | HY-B0779A-10mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.88% | 10mg |
¥1500 | 2025-04-16 | |
| MedChemExpress | HY-B0779A-50mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.88% | 50mg |
¥4500 | 2025-04-16 | |
| MedChemExpress | HY-B0779A-100mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.88% | 100mg |
¥7500 | 2024-04-18 | |
| TRC | T103505-10mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 10mg |
$207.00 | 2023-05-17 | ||
| TRC | T103505-25mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 25mg |
$460.00 | 2023-05-17 | ||
| TRC | T103505-50mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 50mg |
$856.00 | 2023-05-17 | ||
| TRC | T103505-100mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 100mg |
$ 1800.00 | 2023-09-06 | ||
| MedChemExpress | HY-B0779A-10mM*1 mL in DMSO |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.88% | 10mM*1 mL in DMSO |
¥1650 | 2025-04-16 | |
| MedChemExpress | HY-B0779A-5mg |
(5E,9E,13E)-Teprenone |
3796-63-2 | 99.88% | 5mg |
¥937 | 2025-04-16 |
(5E,9E,13E)-Teprenone Related Literature
-
Rongyan Guo,Tao Li,Shuie Shi J. Mater. Chem. C, 2019,7, 5148-5154
-
Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
-
Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
-
Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
-
Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
Additional information on (5E,9E,13E)-Teprenone
Introduction to (5E,9E,13E)-Teprenone (CAS No. 3796-63-2)
CAS No. 3796-63-2 identifies a specific organic compound known as (5E,9E,13E)-Teprenone, which belongs to the class of sesquiterpenoids. These compounds are naturally occurring terpenes with a molecular structure that often exhibits significant biological activity. (5E,9E,13E)-Teprenone has garnered attention in the scientific community due to its unique chemical properties and potential applications in pharmaceutical research and biotechnology.
The molecular formula of (5E,9E,13E)-Teprenone is C??H??O?, reflecting its sesquiterpene backbone with hydroxyl and ketone functional groups. This structural configuration contributes to its reactivity and interaction with biological targets. The stereochemistry defined by the (5E,9E,13E) nomenclature indicates specific double bond placements in the molecule, which are critical for its biological function.
Recent advancements in chemical synthesis have enabled more efficient production of (5E,9E,13E)-Teprenone, making it more accessible for research purposes. Researchers have been exploring its potential in various fields, particularly in drug discovery and natural product chemistry. The compound’s ability to modulate biological pathways has led to investigations into its pharmacological effects.
One of the most compelling aspects of (5E,9E,13E)-Teprenone is its demonstrated role as a bioactive molecule. Studies have shown that it interacts with multiple cellular targets, including enzymes and receptors involved in inflammation and oxidative stress. These interactions make it a promising candidate for developing therapeutic agents targeting chronic diseases such as cardiovascular disorders and neurodegenerative conditions.
The pharmacokinetic profile of (5E,9E,13E)-Teprenone is another area of active investigation. Research indicates that it exhibits moderate solubility in both water and lipids, suggesting potential for oral and topical administration. Additionally, preliminary studies have explored its stability under various conditions, which is crucial for formulating effective pharmaceutical products.
In the realm of natural product chemistry, (5E,9E,13E)-Teprenone is notable for its isolation from specific plant sources. These plants often thrive in unique ecological niches, contributing to the compound’s rarity and value. The extraction and purification processes require specialized techniques to maintain the integrity of the sesquiterpene structure.
Current research is also focusing on synthetic derivatives of (5E,9E,13E)-Teprenone, aiming to enhance its bioavailability and therapeutic efficacy. By modifying its chemical structure through functional group interconversion or stereochemical manipulation, scientists hope to develop more potent and selective drugs based on this scaffold.
The role of (5E,9E,13E)-Teprenone in medicinal chemistry extends beyond isolated applications. It serves as a model compound for understanding how sesquiterpenoids interact with biological systems. This knowledge can be leveraged to design novel molecules with improved pharmacological properties.
As interest in natural-derived compounds grows due to their unique structures and low toxicity profiles,(5E,9E,13E)-Teprenone exemplifies the importance of preserving biodiversity-rich ecosystems. Conservation efforts may play a critical role in ensuring sustainable access to this valuable resource.
The future directions for research on (5E,9E,13E)-Teprenone include exploring its potential in combinatorial therapy regimens. By pairing it with other bioactive compounds, researchers aim to develop synergistic treatments that could address complex diseases more effectively than single-agent approaches.
In conclusion,(5 E , 9 E , 13 E ) - T e p r e n o n e ( C A S N o . 3 7 9 6 - 6 3 - 2 ) represents a fascinating subject of study with significant implications for pharmaceutical science. Its unique chemical properties and biological activities make it a valuable asset in drug development efforts aimed at addressing global health challenges.
3796-63-2 ((5E,9E,13E)-Teprenone) Related Products
- 6809-52-5(Teprenone)
- 3879-26-3(Nerylacetone)
- 3796-70-1((E)-6,10-Dimethylundeca-5,9-dien-2-one)
- 762-29-8(Farnesalacetone)
- 21978-49-4(5,9,13,17,21,25,29,33-Pentatriacontaoctaen-2-one,6,10,14,18,22,26,30,34-octamethyl-, (5E,9E,13E,17E,21E,25E,29E)-)
- 1117-52-8(E,E-Farnesylacetone)
- 689-67-8((E/Z)-Geranylacetone)
- 24199-46-0(5-Octen-2-one,6-methyl-)
- 13125-74-1(5,9-Dodecadien-2-one,6,10-dimethyl-)
- 175655-42-2(5-Hepten-2-one,5-ethyl-, (E)- (9CI))